Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Colorectal Cancer Screening Market Value Analysis: What Growth Is Expected Over The Forecast Period?
The colorectal cancer screening market has demonstrated significant expansion in recent years. It is anticipated to increase from $16.56 billion in 2025 to $17.56 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.1%. The market’s past growth can be attributed to factors like the rising occurrence of colorectal cancer, the expansion of national screening guidelines, increased awareness regarding the benefits of early diagnosis, the adoption of fecal-based screening methods, and improved access to diagnostic services.
The colorectal cancer screening market is anticipated to experience substantial expansion in the coming years. By 2030, its valuation is projected to reach $22.06 billion, demonstrating a compound annual growth rate (CAGR) of 5.9%. This projected growth during the forecast period is primarily driven by factors such as a rise in screening participation among younger demographics, enhanced incorporation of AI into endoscopy techniques, the proliferation of screening initiatives supported by telehealth, a heightened emphasis on individualized cancer risk evaluation, and increased financial commitments to preventive healthcare infrastructure. Significant trends expected during this period involve a greater embrace of non-invasive screening methods, the expanding deployment of AI-assisted colonoscopy systems, a surging need for at-home stool testing kits, the broadening of population-level screening programs, and a strengthened commitment to early diagnosis and preventive care.
Download A Free Sample Report For Comprehensive Market Insights:
#Colorectal Cancer Screening Market Demand Drivers Creating New Revenue Opportunities
The escalating number of older individuals is projected to fuel expansion within the colorectal cancer screening market moving ahead. This demographic shift signifies a rising proportion of elderly people (usually those aged 65 and above) compared to the working-age group, largely resulting from extended life expectancies and decreased birth rates. Longer life expectancies and fewer births contribute to the expansion of the aging population, consequently increasing the worldwide share of older adults. Colorectal cancer screening plays a crucial role in addressing the requirements of the expanding elderly demographic. It facilitates early diagnosis and preventative actions, which are vital for tackling the increased cancer risk among older individuals and improving their general health results. As an illustration, in January 2024, data from the Population Reference Bureau (PRB), a US nonprofit research entity, indicated that the count of Americans aged 65 and older is projected to climb from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Concurrently, their share of the total populace is forecast to expand from 17% to 23%. Consequently, the expansion of the aging population is a key driver for the colorectal cancer screening market.
Colorectal Cancer Screening Market Segmentation And Category Breakdown
The colorectal cancer screening market covered in this report is segmented –
1) By Type: Stool-Based, Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), Stool Deoxyribonucleic Acid (DNA) Test, Colonoscopy, Other Types
2) By Age Group: Below 50 Years, 50-64 Years, Above 65 Years
3) By End User: Hospitals And Clinics, Clinical Laboratories, Diagnostic Imaging Centers, Other End-Users
Subsegments:
1) By Stool-Based: Stool-Based Tests
2) By Fecal Immunochemical Test (FIT): High-Sensitivity FIT, Low-Sensitivity FIT
3) By Fecal Occult Blood Test (FOBT): Guaiac FOBT, Immunochemical FOBT
4) By Stool Deoxyribonucleic Acid (DNA) Test: Multi-Target Stool DNA Test, Single-Target Stool DNA Test
5) By Colonoscopy: Diagnostic Colonoscopy, Therapeutic Colonoscopy
6) By Other Types: Virtual Colonoscopy, Flexible Sigmoidoscopy, Capsule Endoscopy
Colorectal Cancer Screening Market Innovation Trends: Which Developments Are Transforming The Industry?
Leading companies operating in the colorectal cancer screening market are concentrating on developing innovative solutions, such as non-invasive multi-target stool ribonucleic acid (RNA) colorectal cancer screening tests. These aim to provide an accessible and effective method for the early identification of colorectal cancer, thereby enhancing patient outcomes and encouraging broader participation in screening. Non-invasive multi-target stool RNA colorectal cancer screening tests work by analyzing RNA markers from a stool sample to detect the presence of colorectal cancer or precancerous lesions, offering a non-surgical approach for early detection. For example, in May 2024, Geneoscopy Inc., a US-based life sciences company, announced the U.S. Food and Drug Administration (FDA) approval of ColoSense. This product employs RNA biomarkers for a non-invasive, stool-based screening that showed 93% sensitivity for detecting colorectal cancer and 45% sensitivity for advanced adenomas. Its significance is rooted in its high accuracy, particularly within younger populations, and its potential to boost screening rates by offering a less invasive alternative to traditional methods.
Colorectal Cancer Screening Market Competitive Analysis Of Major Industry Participants
Major companies operating in the colorectal cancer screening market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Medtronic plc, Siemens Healthineers, FUJIFILM Holdings Corporation, GE HealthCare, Boston Scientific Corporation, Olympus Corporation, Hologic Inc., bioMérieux SA, QuidelOrtho Corporation, Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, Guardant Health Inc., Eiken Chemical Co. Ltd., HemoCue AB, Clinical Genomics Inc., Polymedco LLC, Hemosure Inc., Geneoscopy Inc., Novigenix SA
Access The Complete Colorectal Cancer Screening Market Report:
Colorectal Cancer Screening Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the colorectal cancer screening market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the colorectal cancer screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.